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Abstract
INTRODUCTION: In 2015 lower respiratory infections (LRI) were the fifth leading cause of
death and the leading cause of death for children under five years old. Despite increasing
advances in viral detection technology, etiology is never established for a large portion of viral
respiratory infections. The most recent of such advancements- next-generation sequencing
(NGS)- has greatly improved the ability to discover and/or identify rare or novel viruses.
However, NGS platforms are still not feasible in a clinical laboratory due to cost, complexity,
personnel, etc. The ability to screen for unknown viruses using technology that is already present
in most clinical laboratories would offer an efficient, cost-effective way to determine which
samples may benefit from further testing with NGS.
OBJECTIVES: Establish a methodology for general screening of clinical respiratory samples
for unknown or unidentified viruses.
METHODS: Clinical nasopharyngeal swabs collected in January 2017 were examined based on
the results of the hospital’s virus PCR panel; samples testing negative for all viruses on the panel
were screened for the inflammatory host biomarker for viral infection CXCL10 using an ELISA.
CXCL10-positive samples were tested for viruses not included on the panel to ensure the
presence of a “true unknown” virus. Potential NGS approaches were concurrently investigated
using rhinovirus-positive samples from the same population.
RESULTS: Out of 251 patients with negative viral results from the clinical laboratory, 60 were
found to express a high level of CXCL10 in their sample, indicating a likely viral infection.
Twenty-eight of these were found to contain coronaviruses, and the remaining 32 were declared
“unknown.” These unknown samples will undergo further testing through a variety of techniques
to determine the identity of any virus present in the sample.

CONCLUSION: Protein host biomarker CXCL10 is produced in human respiratory epithelial
cells in the presence of viral infection. Screening of respiratory samples for CXCL10 provides a
pan-viral test that does not require knowledge of a specific pathogen; this study demonstrated a
feasible workflow that could be used to screen large numbers of clinical respiratory samples for
the presence of unknown viruses using technology that is already widely used in clinical
laboratories. This screening assay could serve as a low-cost way to identify samples containing
viral pathogens that otherwise would not be detected; such samples could then be sequenced to
identify the infectious agent.
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Background
Burden of respiratory disease
Respiratory infections are a leading cause of morbidity, mortality, and disability, and present a
substantial economic burden in the form of hospitalizations and health care costs.1,2 Lower
respiratory tract infections (LRIs) make up the majority of serious clinical cases, and are
responsible for up to 4 million annual deaths globally.2 LRIs are the cause of more global deaths
than HIV, TB, and malaria combined, and disproportionally affect children under the age of 5.1,2
Upper respiratory infections (URIs), while not generally as clinically severe, still account for
millions of outpatient visits and over 20 million lost days of work or school.3 In addition, patients
with URIs may develop complications, particularly in the presence of respiratory comorbidities
like asthma or COPD.1

While LRIs like pneumonia may be caused by bacteria, only about 10-15% of URIs are
attributed to bacterial infections, with the majority attributed to viral infections.4 Viruses pose a
unique challenge in detection and diagnostics, and very often the etiologies of LRIs are never
conclusively established (Graf et.al estimated that only 20-60% of cases of community-acquired
pneumonia (CAP) have a detectable pathogen).5 There are several reasons for this: viral genomes
(particularly in RNA viruses) are highly prone to mutations, single nucleotide polymorphisms
(SNPs), and other forms of genetic diversity, which can lead to difficulty in identification.6,7,8 In
addition, unlike bacteria or fungi there is no common genetic feature that all viruses share,
making the creation of a pan-viral assay much more challenging.9,10 Thus, the inherent issue with
clinical virology assays is that one must know which specific pathogen is being looked for when
testing. With so many respiratory infections lacking a detectable pathogen even after exhaustive
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testing, it follows that there must be yet-unidentified viruses circulating in humans and causing
clinical disease.
Virus detection and discovery methods
Culture
Researchers and clinicians have developed different methods for virus discovery and
identification over the years, the most traditional being viral culture. In viral culture, a sample
from a patient or other source is inoculated into a variety of established cell lines, and any
observable cytopathic effects are evaluated.6,9,11 There are many benefits to cell cultures, and
they are often used in conjunction with newer, more complex assays.12 Cultured cells and
supernatants are a source of isolated, concentrated virus that can then be used for electron
microscopy, serology assays, and sequencing methods.6,9,13 Culturing is the best way to isolate
and amplify a virus, and can be done without knowing what kind of virus may be present.9,13

The limits of cell cultures lie in the specific cell lines that are inoculated. Different pathogens
thrive in different environmental conditions and often have specific requirements in order to
survive and replicate.12 Many viruses may not grow on traditionally-used cell lines, or may not
show any visible cytopathic effects. 6,12,14 Therefore, a negative culture does not necessarily
indicate that the original sample contains no virus. This can sometimes be solved by culturing
cells specific to the original environment, like human airway epithelial cells (HAE) for the
growth of respiratory viruses.14 Another potential issue in viral cell culture is the possibility of
mutations after several passes; selective pressure can result for specific strains or types of virus
that are most equipped for the cell lines being used (although this issue is arguably more relevant
for downstream research such as pathogenicity determination and assay development).6,7,12
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Polymerase Chain Reaction
The polymerase chain reaction (PCR) is one of the most common viral detection methods used in
clinical laboratories. Briefly, samples are combined with small genetic segments (primers)
complementary to the gene or area of interest that a specific pathogen is known to contain. This
allows for the exponential replication of the target sequence, the concentration of which can be
measured and quantified to determine the relative amount of that sequence – and therefore that
pathogen – in a sample. PCR (or reverse-transcription PCR for RNA viruses) assays in clinical
settings are generally sensitive enough to detect very low levels of pathogen.

The downside of PCR, when it comes to virus discovery, is that the sequence of the pathogen
must be known in order to create pathogen-specific primers and probes. Primers may be made
that recognize a target common to a virus family or species, but even then the investigator must
have an idea of what kind of virus may be present in the sample.15 Many clinical laboratories
have multiplexed PCR panels that allow for the testing of many viruses in one assay. This lowers
the workload of testing, but still only tests for specific viruses, and may miss viruses not on the
panel or even particularly divergent strains of panel viruses.16,17

Although perhaps not sufficient on its own, PCR technology is still an integral part of newer
sequencing methods for viral discovery: it is used to identify certain genomic fragments, amplify
target sequences, and other similar steps as explained in the next section.
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Next Generation Sequencing
Sequencing all or part of an organism’s genome and comparing it to reference sequences has
become a promising technology in virus discovery and characterization. Metagenomics using
next generation sequencing (NGS) technologies allows for the detection and identification of all
genetic information present in a sample; the process has been used to characterize the viral
population of environmental samples such as ocean water or waste.6,11,18 NGS can be used to
amplify and sequence an unknown viral genome, which can then be compared to reference
sequences using bioinformatic software.10,19

The benefit of NGS is that it is sequence-independent; that is, it does not require a priori
knowledge of the identity or sequence of any viruses in the sample.5,15 Samples go through an
enrichment (of viral particles) and/or depletion (of host DNA) process and are fragmented and
amplified using PCR or similar technology. Those fragments are then sequenced in parallel,
creating millions of “reads” of short DNA sequences that are segments of the entire sequence of
the original sample. These reads are then analyzed and aligned to known reference sequences.

There are inherent challenges present when using NGS for viral discovery. First, in clinical
samples the amount of viral nucleic acid is usually much lower than host DNA and RNA.11,18,19
This means that, without certain preparation steps, any viral reads will be vastly outnumbered
and therefore more difficult to detect and identify.7,10 For this reason, samples are usually put
through either a viral enrichment process or a background nucleic acid depletion procedure.19,20
Enrichment methods include ultracentrifugation and filtration to concentrate viral particles and
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remove non-viral nucleic acid.11 Depletion is generally done with a DNAse step during the
sample preparation process.9,11,12

Sequencing is only as useful as its reference library. Reads are identified by comparing them to
known sequences in vast reference libraries.20,21 This poses a problem when dealing with a truly
novel virus or particularly divergent strains of known viruses; a matching sequence may not be
found or identified as such in the available databases, making conclusions about the identity of
sequences virus difficult.9,20 Genomic material for which no match is found (and has been
confirmed as non-human, non-fungal, and non-bacterial) is sometimes referred to as viral “dark
matter,” and it makes up a significant amount of reads in many viral metagenomics studies.9,20,21
Most viruses that have been discovered to date using NGS had enough homology to known
viruses to allow for the preliminary information on the family or species, which can then inform
further identification processes.4,12,17

While still largely confined to research laboratories, there are many clinical reasons to develop
methods to identify a virus using NGS. During an ongoing epidemic, identifying the causative
agent early allows for the quick development of faster PCR tests to identify cases and inform the
beginning of vaccine or antiviral work.6,22 Deep sequencing also has the potential to identify
distinct subtypes or SNPs that confer different resistance profiles or enhanced virulence.5,10
Sequencing has enabled or aided in the discovery of many clinically significant viruses,
including human metapneumovirus (hMPV), human bocavirus (HBoV), distinct subtypes of
coronavirus, and others.4,23,24
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Screening before NGS
Next generation sequencing is a complex process that comes with often prohibitive costs and the
need for advanced computing power and training. For this reason, it is largely used for research –
either in metagenomics or clinical case studies – rather than as a diagnostic tool. At this point in
the technology, it would be impractical to implement NGS as a general diagnostic test to be used
in the same context as PCR panels or immunoassays.

CXCL10
CXCL10 is a pro-inflammatory chemokine produced by many different kinds of cells in the body
in response to infection or cell damage.4,23,24 It serves as a chemoattractant, recruiting CD4+ Tcells, monocytes, and NK cells and inducing further cytokine secretion.25,26 Its role in
inflammation has been studied in many different contexts: it has been examined as a marker of
increased risk of allogenic graft rejection, hepatitis-induced liver fibrosis, pre-term labor, and
HIV progression.26–28 Previous work from the Foxman Lab showed that CXCL10 may be useful
as a host-derived biomarker for viral diagnostics, as it is highly expressed in respiratory
epithelial cells in the presence of an active viral infection.16 That study used nasopharyngeal
swabs and showed that CXCL10 mRNA and protein levels were a good predictor of the presence
of one or more viruses.16 Importantly, that study also showed that bacterial infections did not
result in the same activation of CXCL10, confirming that this marker may be effective in
distinguishing between viral and bacterial respiratory infections.16
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CXCL10 as a screening method
The goal of this project was to begin to bridge the gap between the clinical laboratory and the
power of next generation sequencing, by developing a method to screen clinical samples to
identify those containing truly
unknown viruses and evaluate

Table 1: Respiratory Viruses in Yale New Haven
Hospital semi-quantitative PCR Panel

potential workflows to identify those

Adenovirus

viruses using NGS. We sought to

Human Metapneumovirus (hMPV)
Rhinovirus (RV)

develop a methodology to utilize

Influenza A and B

CXCL10 as a way to screen patient

Respiratory Syncytial Virus (RSV)

samples for unknown or unidentifiable
respiratory viruses. To this end we
examined clinical respiratory samples

Parainfluenza 1-3, 4*(PIV 1-4)
Coronavirus*
*added to panel after beginning of study
Table 1: Viruses included in YNHH respiratory panel

(nasopharyngeal swabs) that had tested negative for all viruses on the clinical virus PCR panel to
attempt to determine if any contained a virus that is not included in that panel, and so went
undetected in the clinical laboratory. These relevant samples can then continue on to NGS.

Methods
Samples
1,109 samples of frozen viral transport media from nasopharyngeal swabs were supplied by the
clinical laboratory at Yale New Haven Hospital (YNHH). Samples were collected in January
2017, and transport media was kept at -80°C. Additionally, individual test information was
provided by the clinical laboratory to break down all viral respiratory tests that had been run on
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the provided nasopharyngeal

160
140

tested using a clinical PCR
panel consisting of Influenza A
and B, adenovirus, respiratory

Number of Cases

swabs. Samples had been

syncytial virus (RSV),

100
80
60
40
20
0
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/2
1 2 4 -1
/ 1 2/ 3
0 0
1 1 -1 2
/ 2 / 16
1 1 6 -1
/ 2
1 0 5-1 / 2
/ 2 1 /1
2
1
1 0 -1 0
/ 8 / 28
-1
9 / 0 /1
24 4
9 / -9/ 3
10 0
8 / 9/ 16
2
8 / 7-9
13 /2
7 / 8/ 19
30
7 / -8
16 /5
-7
/
7 22
6 / /2 -7
1 1 /8
/ -6
5 / /1 7
28
5 / -6
14 /3
4 / 5/ 20
3
4 / 0-5
16 /6
-4
/
4 / 22
2
3 / -4
0 3 1 9- /8
/ 0 3/ 2
0 2 5 -0 5
/ 1 3/ 1
0 1 2 -0 1
/ 2 2/ 1
0 1 9 -0 8
/ 1 2/ 0
0 1 5 -0 4
/ 0 1/ 2
1- 1
01
/0
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rhinovirus (RV), Parainfluenza

120

viruses 1-3 (PIV), and human
metapneumovirus (hMPV).

RSV1,2

Influenza A (subtyped)

Influenza B

Parainfluenza types 1,2,3

Adenovirus1,2,3

HMPV1,2

Rhinovirus2

120

104

Out of the 1,109 samples, 732
had been tested with a
complete clinical PCR panel
(see Table 1 for a list of
included viruses). Of those,

Positive Tests

100
80

64

60
40
20

24
3

10

8

1

0
Adeno

hMPV

Flu A

Flu B

Paraflu

RSV

Rhino

Figure 1: URI cases at YNHH in 2017, by week (a); Positive tests
per virus, week 4 (b)

588 were negative (80.3%). Samples
were organized by week; week 4, from January 22 to January 31, contained the most samples
(n=266), so these samples were chosen for further analysis (see Figure 1a and 1b for a weekly
breakdown of URI cases at YNHH). Some samples in the provided record did not have a
corresponding sample or were mislabeled, bringing the final number of analyzed samples to 251.
Data was collected on these samples including patient demographics, information on the
encounter in which the sample was taken, and comorbidities. Samples were deidentified and
chart review procedure was approved by Yale Human Investigations Committee. Symptoms
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were pulled from ICD-9 codes and chart notes from the encounters for which the specific
samples were collected.

Additionally, information was collected from 33 samples from the original 1,109 that were
positive for rhinovirus (RV) according to the clinical virus panel. These samples were used in
initial optimization and quality control testing.

251 total
samples

CXCL10 ELISA

Positive

CoV / PIV-4
qPCR

Negative

Further workup

Figure 2: Workflow for PCR-negative samples

The workflow for these samples is shown in Figure 2. First, samples were tested for the presence
of CXCL10 by ELISA. Those that tested positive for CXCL10 were screened for coronavirus
and parainfluenzavirus-4 with qPCR (these are common respiratory viruses that were not
included in the hospital’s panel), and those that were negative were considered true unknowns
and were carried on for further investigation

Method Development and Sample Preparation
Experiments using rhinovirus (RV)-positive samples were done to determine the optimal lysis
buffer and storage conditions that would result in the highest RNA yield. Thawed samples were
prepared using the following methods: thawed samples with added Qiagen AVL buffer and BME
(Sigma) that were tested without being refrozen (referred to as “fresh”), and samples that went
through one freeze-thaw after preparation and before testing. Freeze-thaw samples were
designated as frozen with no additives, frozen with AVL and BME, and frozen with AVL and
10

RNALater RNA stabilization reagent (Qiagen). qPCR was then performed using primers for
HPRT, b-actin, CXCL10, and rhinovirus/enterovirus (Invitrogen). Relative amounts were
RV/EV High

calculated based on b-actin, and are shown for both high
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n

800

sh

of 140 µl were made for RNA isolation, to which 560 µl
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1000
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(viral transport media) was thawed on ice, and two tubes

A

B
+
n
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oz
e

RV/EV Low

to use fresh samples

aliquots were made from each sample: the original sample

M

M
B
+
sh
Fr
e

prepared with AVL and BME, as it would not be possible

In the final workflow used for this project, the following

E

E

was decided that going forward, samples would be

Fr
oz
e

from clinical laboratory results). Based on these results, it

Relative amount

and low levels of rhinovirus in Figure 3 (based on CTs

1×106

Figure 3: Relative amounts of
rhino/enterovirus present in rhinoviruspositive samples under different storage
conditions

original sample was spun down to remove cell debris; 70 µl of supernatant was added to a flatbottom 96-well plate for immunoassay. The remaining supernatant was transferred into a new
tube to be used as extra material if needed. All aliquots, if not immediately used, were frozen at 80° C.

RNA extraction
Viral RNA extraction was carried out on samples using the Qiagen QIAmp Viral RNA Mini kit
with no added carrier RNA. Samples had been frozen with AVL lysis buffer as described above,
which is the first step of the Qiagen protocol, so those aliquots could be simply be thawed before
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proceeding with the protocol. Extraction was done per kit instructions, with the addition of a 15minute DNAse (Qiagen) incubation step before elution. Samples were eluted in two elutions of
30 µl, the first of which was used to make cDNA. Remaining eluates were stored at -80°C.

cDNA was prepared from extracted RNA using the Bio-Rad iScript cDNA synthesis kit, with 4
µl of Reaction Mix and 1 µl reverse transcriptase added to 10 µl water and 5 µl sample. This was
run on a Bio-Rad T100 Thermal Cycler under manufacturer-recommended conditions. cDNA
was stored at -80° when not in use.

CXCL10 ELISA
Samples were screened for CXCL10 using the R&D Systems Human CXCL10/IP-10 DuoSet
ELISA per manufacturer’s instruction. For each 96-well plate, the assay was performed over the
course of three days. Detection was performed on the final day, and the plates were read using a
VersaMax Microplate Reader (Molecular Devices) at 450 nm.

Standard curves were generated using the manufacturer-provided concentrations of the
standards, and used to calculated CXCL10 concentrations (in pg/ml). The lower limit of the
linear range was 32.25 pg/ml. Samples were run in 1:5 dilutions, making the lower limit of
detection 61.25 pg/ml for original samples.

qPCR
Because the clinical PCR panel did not include coronavirus or parainfluenza-4 virus at the time
that these samples were analyzed, SYBR green qPCR (Bio-Rad) was performed on CXCL10-
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positive samples with CoV and PIV-4 primers.29 Samples that were positive for CXCL10 and
negative for CoV/PIV-4 were considered “true unknowns” to be further investigated. Some
CXCL10 samples were also tested for ß-actin to ensure sample integrity.

Initial Sequence Investigation
The next step in a process for identifying unknown viruses may be NGS. To begin to explore the
best options for this step, eight samples were selected. These included four clinical samples that
were known to be RV-positive (one of which was coinfected with RSV), two RV-infected cell
culture samples (positive controls), and two RV-negative cell culture samples (negative
controls). RNA isolated from these samples using the above protocol was sent to the Yale Center
for Genomic Analysis (YCGA). YCGA performed a low-input library generation protocol (using
the Kapa Biosystems ribo-depletion kit) and sequenced samples using Illumina technology. The
resulting data was sent to both an academic collaborator and a commercial pathogen
identification company for analysis.

RNA isolation and sequencing was chosen over DNA or total nucleic acid based on the high
percentage of RNA respiratory viruses, while recognizing that sequencing RNA may also
recognize DNA viruses that are actively being transcribed. Ribo-depletion was performed to
eliminate host nucleic acids and increase sensitivity to any viral particles.

Results
Results of the procedures are summarized in Figure 4. Out of 251 patient samples, 60 (23.9%)
were found to be CXCL10-positive by immunoassay. Of those 60, 28 (11.2% of original 251
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samples) were found to be positive for CoV,
251
Total samples

using primers that included three different
strains (229E, NL63, OC43). The remaining 32

CXCL10 ELISA

(12.7%) CXCL10-positive samples tested
negative for CoV and PIV-4 via qPCR, and

60
CXCL10 positive

were considered true unknowns.
CoV/PIV-4
qPCR

The 251 samples that made up our study

28
CoV positive

32
CoV/PIV-4 negative

population are described in Table 2. The
average age of the patients associated with the
samples was 59.9. 43.0% were over the age of

Further work-up
(deep squence, cell culture, etc)

Figure 4: Summary of results

65, with 79.2% being over the age of 45. Females accounted for 61.0% of the samples, and the
majority were from Caucasian patients (57%). Most samples came from inpatients (80.5%),
many of whom were admitted from the emergency department. 53.4% of patients presented with
respiratory symptoms and 19.5% were febrile. 10.4% reported cardiac related symptoms, such as
chest pain or pressure, tachycardia, etc. It’s important to note that these symptoms are also
commonly seen in respiratory infections and should not be considered solely indicative of a
cardiovascular problem. The most common comorbidities (33.5%) were respiratory diseases

14

Table 2. Description of samples (n=251)
N (%)*
Age
<5
6-15
16-25
26-45
46-55
56-65
>65
Gender
Male
Female
Race/Ethnicity
White
Black
Hispanic
Other/Unknown
Patient Status
Inpatient
Outpatient
ED
Unknown
Presenting symptoms
Respiratory
Fever
Cardiac
Altered mental state
Fatigue
Other
Comorbidities
Respiratory
Cardiovascular
Diabetes
Cancer
Liver/kidney disease
Other
Ordering Department
General medicine
ICU/Surgery
Oncology
ED
Outpatient
Other/Unknown

9 (3.6)
2 (0.8)
13 (5.2)
28 (11.2)
35 (13.9)
56 (22.3)
108 (43.0)
98 (39.0)
153 (61.0)
143 (57.0)
67 (26.7)
32 (12.8)
9 (3.6)
202 (80.5)
23 (9.2)
21 (8.4)
5 (2.0)
134 (53.4)
49 (19.5)
26 (10.4)
22 (8.8)
8 (3.6)
95 (37.8)
84 (33.5)
67 (26.7)
60 (23.9)
51 (20.3)
48 (19.1)
81 32.3)
148 (59.0)
35 (13.9)
22 (8.8)
20 (8.0)
16 (6.4)
10 (4.0)

*Percentages may not add up to 100% due to multiple symptoms/comorbidities per single patient
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Table 3. Description of PCR-negative samples: CXCL10 negative vs CXCL10 positive (“unknowns”)
PCR neg/CXCL10 neg PCR neg/CXCL10 pos
p-value
(n=191) N (%)†
(n=32) N (%)†
Age
0.038
<5
4 (2.1)
3 (9.4)
6-15
2 (1.1)
0 (0.0)
16-25
7 (3.7)
5 (15.6)
26-45
21 (11.0)
3 (9.4)
46-55
29 (15.2)
4 (12.5)
56-65
42 (22.0)
5 (15.6)
>65
86 (45.0)
12 (37.5)
Gender
0.67
Male
76 (39.8)
14 (43.8)
Female
115 (60.2)
18 (56.3)
Race/Ethnicity
0.16
White
105 (55.0)
24 (75.0)
Black
52 (27.2)
6 (18.8)
Hispanic
25 (13.1)
2 (6.3)
Other/Unknown
9 (4.7)
0 (0.0)
Patient Status
0.68
Inpatient
157 (82.2)
25 (78.1)
Outpatient
15 (7.9)
4 (12.5)
ED
15 (7.9)
3 (9.4)
Unknown
4 (2.1)
0 (0.0)
Presenting symptoms*
Respiratory symptoms
95 (49.7)
20 (62.5)
0.18
Fever
37 (19.4)
6 (18.8)
0.93
Cardiac
20 (10.5)
1 (3.1)
0.32
Altered mental state
16 (8.4)
4 (12.5)
0.50
Fatigue
3 (1.6)
5 (15.6)
<0.001
Other
65 (34.0)
14 (43.8)
0.29
Comorbidities*
Respiratory
68 (33.6)
10 (31.3)
0.63
Cardiovascular
57 (29.8)
5 (15.6)
0.097
Diabetes
49 (25.7)
5 (15.6)
0.24
Cancer
37 (19.4)
8 (25.0)
0.46
Liver/kidney disease
42 (22.0)
4 (12.5)
0.22
Other
62 (32.5)
9 (28.1)
0.63
Ordering Department
0.92
General medicine
113 (59.2)
17 (53.1)
ICU/Surgery
27 (14.1)
6 (18.8)
Oncology
18 (9.4)
2 (6.3)
ED
15 (7.9)
3 (9.4)
Other/Unknown
7 (3.7)
2 (6.3)
Outpatient
11 (5.8)
2 (6.3)
Comparisons were performed using a global c2 test except where indicated with (*), where individual c2 was used.
(†) Some percentages may not add up to 100% due to multiple symptoms/comorbidities per single patient
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(including asthma and COPD), followed by cardiovascular disease (26.7%), and diabetes
(23.9%).

Table 3 shows characteristics of the 223 PCR-negative samples (the original 251 minus the 28
that tested CoV positive), comparing those that were CXCL10-positive (i.e. our unknowns) vs
those that were CXCL10-negative (those that are presumably virus-negative). There was a
statistically significant difference in age between the two groups (p=0.038); in general, more
CXCL10-positive patients were under the age of 25, although the highest percentage of patients
in both populations were over the age of 65. The only other significant difference between the
populations was that CXCL10-positive patients were more likely to report fatigue as one of their
symptoms upon presentation (p<0.001).

Briefly, 37.5% of CXCL10-positive samples (n=32) were over the age of 65, with 9.4% under
the age of five. Like the CXCL10-negative population, the majority of patients were female
(56.3%), white (75.0%), and were inpatients at the time of sample collection (78.1%). 62.5% of
these patients presented with respiratory symptoms of some kind, and 31.3% had respiratory
comorbidities. The most common comorbidity after respiratory among these 32 patients was
cancer (25.0%). Breakdowns of what was included in each category in symptoms and
comorbidities can be found in Supplementary Tables 1 and 2.

At the time that these samples were collected, YNHH’s clinical laboratory did not test for
parainfluenza-4 virus or any coronaviruses. Because of the high incidence demonstrated by this
study, the YNHH lab has now added PIV-4 and CoV to its standard PCR panel.
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CXCL10 Concentration
For the purpose of this study, any discernible CXCL10 (that is, above the lower limit of detection
of 161.25 pg/ml) was considered positive. CXCL10 concentrations for unknowns as well as
those that tested coronavirus-positive, sorted highest to lowest, are shown in Figure 5. The two
populations had similar distributions of CXCL10 concentrations, with the exception of the two
highest CoV samples which
had higher concentrations

6000

than the highest unknowns.

5000

levels between known viruspositive samples and
“unknowns” further support

[CXCL10] pg/ml

These comparable CXCL10
4000

PCR
negative
CoV positive

3000

2000

the hypothesis that the PCR1000

negative “unknown” samples
contain a virus. Interpretation
of CXCL10 levels will

0
Figure 5: [CXCL10] for "unknown" samples and coronavirus positive samples. Dotted lines
represent potential cut offs that result in sensitivities of 50%, 60%, 76%, and 81%. Sensitivities
estimated based on data from Landry and Foxman (2018)

depend on its use; likely, a
qualitative positive/negative result would serve the purpose of most assays likely to utilize this
method. In that case, a cut-off value would need to be established to define a “positive” result.
Figure 5 shows possible cut-off concentrations resulting in different sensitivities using data from
Landry and Foxman.16 Cut-offs of 107 pg/ml, 155 pg/ml, 488 pg/ml, and 809 pg/ml result in
sensitivities of 50%, 60%, 76%, and 81%, respectively. Applying these cut-offs to the 32
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CXCL10-positive samples from this study would result in the following percentages of our
original “unknowns” to be considered positive: 100% (32/32), 91% (29/32), 47% (15/32), and
31% (10/32) with 50%, 60%, 76%, and 81% sensitivity, respectively. It is important to note that
Landry and Foxman used a different technology to quantify CXCL10 than did this study (BioPlex immunoassay vs ELISA). Further studies with samples containing known concentrations of
specific viruses would be needed to better determine a cut-off based on specificity and
sensitivity.

Sequencing Results
The commercial company detected some but not all of the viruses known to be present in the
virus-positive samples, and those that were detected generally had very few reads. The report
Sample

Organism

No. of reads

Rhinovirus A
Positive Control 1

Pseudomonas veronii

20
Environmental
bacteria

Rhinovirus A
Positive Control 2

RV-positive 1

RV-positive 2

RV-positive 3

RV-positive 4

6,372
20

Pseudomonas
pseudoalcaligenes

Environmental
bacteria

5,408

Acanthamoeba royreba

Non-pathogenic
amoeba

4,095

Treponema pedis

Bovine pathogen

2,747

Zygosaccharomyces bailii

Fungi involved in
food spoilage

5,114

Macrocystidia cucumis

Inedible mushroom

1,151

Macrocystidia cucumis

Inedible mushroom

3,711

RSV

6,518

Rhinovirus B

31

Corynebacterium
propinquum
Brachybacterium muris

(Negative Control 1)

Leucobacter sp.

(Negative Control 2)

Zygosaccharomyces bailii

Normal flora
Non-pathogenic
bacteria isolated from
mouse liver
Environmental
microbacteria
Fungi involved in
food spoilage

92,148
5,298
5,452
5,687

Table 4: Number of reads of expected clinical virus (if detected) and most
abundant organism for six rhinovirus-positive and two negative control samples
from commercial pathogen-identification report.
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also listed a myriad of other organisms in both the rhinovirus-positive samples and the negative
control cells. These included a murine malaria pathogen, an oceanic diatom, plant pathogens, and
one fungus that is actually an edible mushroom (See Table 4). It is important to note that this
company’s methods are proprietary, and they largely work with DNA rather than RNA. Our
bioinformatics collaborators in the Handley group at Washington University in St Louis did
detect rhinovirus in all six positive samples, although the sensitivity was still low (number of
rhinovirus reads ranged from 1-528). The Handley group did not report environmental
contamination at the same level as the commercial company (data not shown).

Methods to obtain a higher RNA yield and as such prepare better libraries are discussed in the
“Next Steps” section of this paper.

Discussion
Characterization of Unknowns
This project serves to introduce a series of procedures that improve the efficiency of identifying
patients with unidentified respiratory viruses, and a potential pipeline that those samples may
move through for such identification. CXCL10 is a proinflammatory cytokine that is released by
cells during a viral infection. Its main function is as a chemoattractant for T-cells, but it may also
play a role in other aspects of the immune response.25 CXCL10 is one of a family of genes that
are highly induced by interferon signaling, and is one of the most highly induced proteins in
nasal epithelial cells in the presence of viral RNA.16 Previous work from the Foxman laboratory
showed that CXCL10 mRNA and protein levels are highly correlated with the presence of a viral
infection, using nasopharyngeal swabs from symptomatic patients.16 Because CXCL10 is
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released as part of a specifically antiviral response, it is a promising option for a pan-viral marker
for respiratory viral infection.

In this study, clinical nasopharyngeal swabs for which a clinical respiratory virus panel had been
ordered were obtained for the month of January 2017, 144 of which tested positive for at least
one virus on the clinical PCR panel and 588 of which no virus was detected. (The PCR panel
included Influenza A and B, Parainfluenza 1-3, Adenovirus, Rhinovirus, RSV, and hMPV). A
sub-population of 251 negative samples were then tested for CXCL10 to attempt to identify
samples containing viruses that were not included on the hospital’s panel. These may include
rare or unusual viruses, divergent sub-species or strains of a common virus, a virus that is
generally not pathogenic but may become so in certain settings (i.e. immunosuppression), or
novel viruses. Sixty panel-negative samples (23.9%) tested positive for CXCL10 (>161 pg/ml
based on standard curve) using a standard ELISA. Of those 60, 28 ultimately tested for other
known viruses that were not on the original panel, but 32 remained undiagnosed (11.2% and
12.7% of the original population, respectively).

There was a small but significant difference (p=0.038) in age distributions when the 32
“unknowns” were compared with the rest of the PCR-negative/CXCL10-negative samples.
While both populations had the highest percentage of people in the over-65 age group, a higher
percentage of the remaining patients in the CXCL10-positive (“unknown”) population were
under the age of 25. Assuming that our assumption is correct – that the unknown samples do
indeed contain a virus – it is reasonable to see more children represented, due to their potentially
higher susceptibility to infection. Notably, unknown samples had more patients under the age of
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five: 9.4%, compared to only 2.1% in CXCL10-negative samples. The only other statistically
significant difference was that patients with CXCL10-positive/unknown samples were more
likely to list fatigue as a symptom upon initial presentation (p<0.001). While it would be
reasonable to attribute high levels of fatigue to virus-positive samples, if that were the case we
would also likely expect to see significant differences in other symptoms (such as fever) between
the two populations. This difference was not observed. However, all patients were judged to
need a nasopharyngeal swab from the clinical staff – likely decisions on whether or not to screen
for CXCL10 will be due to overall presentation rather than on specific symptoms. The
populations were similar in all other variables, including race and gender, comorbidities, and
immunosuppressed status (considered when patient met one or more of the following criteria:
HIV-positive, diagnosed with cancer, currently pregnant, or recent transplant donor or recipient.
Data not shown). This suggests that there is no factor shared by these 32 patients that may
produce elevated CXCL10 levels in the absence of a viral infection.

Initial sequencing results
The next step in a potential virus identification pipeline is identification of the unknown
pathogen. To this end, RNA from rhinovirus-positive clinical samples (isolated using the
described method) as well as positive and negative cell culture controls was sequenced to
determine optimal library preparation protocols and data analysis methods. RNA was chosen
over DNA or total nucleic acid to take advantage of the fact that the majority of respiratory viral
pathogens are RNA viruses; the use of a DNAse step and ribo-depletion method could then be
used to increase sensitivity to RNA virus particles. Importantly, RNA sequencing may also be
able to identify the presence of actively replicating DNA viruses.
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As was expected, clinical samples had very low levels of RNA, generally under 20 ng/ml (data
not shown). To ensure that an adequate number of reads could be detected, the first library
preparation was carried out with a low-input amplification step. Low-input protocols involve
additional amplification of original sample in order to increase the relative amount in the sample.
However, subsequent data analyses (described below) reported a high amount of environmental
contamination, possibly due to the nonspecific amplification performed during the low-input
library preparation. For this reason, a low-input protocol was not used in subsequent library
preparations. Subsequent sequencing of clinical samples without a low-input protocol greatly
reduced background and false positive reads (data not shown).

It could be argued that the negative clinical PCR results for some or all of these samples could be
due to low amounts of or highly degraded RNA, rather than the true absence of virus. To rule out
this possibility, 23/32 “unknown” samples included primers for the house-keeping gene ß-actin.
All were highly positive, indicating that sample RNA was of high enough integrity to be detected
by qPCR. (data not shown).

Data analysis was performed concurrently by a commercial sequencing company and by the
Hadley group at Washington University. The company did not detect rhinovirus in all of the RVpositive samples, and when it was detected it was in amounts much lower than what would be
expected based on PCR results. Additionally, they reported the detection of a massive number of
other microorganisms (bacteria, fungi, and protozoa), the large majority of which appeared to be
either environmental contamination or misidentified reads. The Hadley group did not report the
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same level of contamination, and was able to detect rhinovirus in all positive sample (as well as
RSV in a coinfected sample).

There are several factors to be considered here. The Hadley group reported that water – even
laboratory grade DI or RNAse-free water- often contains reads from viruses or bacteria. For this
reason, in many sequencing labs it is standard to sequence the water used in the preparation
processes, to establish a background that may then be subtracted from the final result. This was
not done in this case, and likely is a source of at least some of the environmental contaminants
detected. Secondly, there can be significant overlap between viral sequences and the human
genome, which the Handley lab protocol takes into account. The protocol used by the
commercial company is proprietary, and thus it is not known if these or other potential issues are
considered as part of their procedure.

Clinical benefits
Identifying unknown viruses present in respiratory samples has several benefits. First, knowing
what virus is present can affect treatment or follow-up decisions, and generally improve patient
care. Secondly, identifying these viruses can give important information about what pathogens
are circulating in the hospital (or wider) population, which may be useful for observing trends,
adjusting testing or treatment protocols, or recognizing an epidemic or emerging virus in the
early stage. This was illustrated in the course of this study, when the YNHH clinical laboratory
added four new viruses (PIV-4 and three strains of CoV) to their standard panel based on how
many of them were found over the course of this project.

24

This sequence of methods presents a way of efficiently screening large numbers of patients for
unknown respiratory viruses using technology that is already well established in clinical
laboratories. In one possible algorithm, any samples that are negative for the PCR panel would
automatically be sent for a CXCL10 ELISA. Any samples positive on the ELISA would be
considered unknown and could then be sent for sequencing. ELISA assays can be batched, so
many samples can be run at once – potentially between 30-40 in a standard 96-well plate.

This method could also have potential for wider surveillance programs outside of a clinical
setting. This is particularly relevant since respiratory viruses have been the cause of the most
important outbreaks and epidemics of the last 20 years including SARS, MERS, and H1N1
influenza.19

While the PCR and ELISA process can be completed in a day or two, sequencing any unknown
viruses likely still takes too much time to be of clinical help to the original patient. However,
identifying and classifying the virus can be useful for future patients – sequencing allows for the
creation of pathogen-specific primers which can then be used for a much faster identification,
and provide a starting point for drug discovery or vaccine trials.10,19,22

Limitations
This project was limited by the samples that were available. These were collected from one week
in January, and as such do not give information on the prevalence of unknown or unusual viruses
during the rest of the year. Respiratory viruses are known to be seasonal, so likely the number of
hospital-panel-negative/CXCL10 positive samples will vary. Similarly, these results may not be
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generalizable to all populations, as the sample study population tended to be older, with more
comorbidities than younger adults or children. However, this was taken to be representative of
the specific population that would likely have their samples tested through this methodology.
Extensive testing for respiratory viruses is generally only done in serious, inpatient cases, and the
population that tends to be most at risk for serious respiratory infection is consistent with our
study population. Similar screening studies at different seasonal points during the year and with
specialized populations would be beneficial.

It may also be important to note that complete clinical data was not available or not collected for
all of the patients in this population. In future studies, evaluating other laboratory results –
particularly other microbiology results – could add valuable information to the categorization of
this population.

The results of this study should not be taken to mean that this protocol will recognize all
unknown viruses that are circulating. The vast majority of respiratory infections are self-limiting,
and patients may only present to an outpatient clinic or not seek care at all. This method is useful
in the population that is most at risk: inpatients who are particularly susceptible to severe
respiratory infections, whether due to underlying disease or extremes of age. Additionally, this
protocol may not distinguish samples in which there is a coinfection of an unknown virus with a
clinically-recognized virus.

Finally, although CXCL10 is a known biomarker for viral infection, it may also be induced or
triggered by other pathogens or disease processes.28,30,31 CXCL10 has been suggested as a
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biomarker for allogenic graft rejection and graft-versus-host disease (GVHD) and as a predictor
of rapid progression of AIDS in HIV-infected patients. 27,28,31 Additionally, it has been shown to
be upregulated in several non-viral disease processes, including cerebral malaria. H. pylori and
Mycoplasma infections, chronic inflammatory placental lesions, various malignant tumors, and
severe Legionella infections.27,28,30 Most of these studies have measured plasma or serum
concentrations, rather than swabs or other cellular samples as in this study. There is also
evidence to show increased levels of CXCL10 during times of general immune system
dysregulation, as in sepsis, multi-agent infections, or gastrointestinal dysbiosis.25,28,30 More
studies of CXCL10 concentrations in the presence of non-viral and/or non-respiratory infections
are needed to further define the function of this protein, and care should be taken when using
CXCL10 in diagnostic decisions, particularly in patients with severe or multifaceted illness.

Future Directions
While this methodology holds promise for identifying samples with unknown viruses, as
demonstrated by the identification of coronavirus-positive samples in “negative” patient samples,
the process of identifying viruses that may be present in those samples is ongoing. To this end,
several parallel investigations are ongoing in the Foxman Lab. These include PCR for additional
untested viruses such as coronavirus type HKU1 and polyomavirus, ruling out fungal infections,
and methods to enrich and amplify the viral signal for more sensitive sequencing. This is being
done using viral culture on human nasal epithelial (HNE) cells. Using cultured cells or
supernatant will result in a sample that is much more concentrated and less contaminated by host
DNA than a clinical sample. Different enrichment methods can serve this same purpose, and may
be helpful if an unknown is proving difficult to culture.
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In order to ensure that only truly unknown pathogens are being sent for sequencing, additional
tests for etiology or coinfection should be done. This may include testing for additional viruses
that are not routinely tested for, such as CMV or EBV. If sample preparation procedure includes
a DNAse step (as ours did), it is advised that DNA is also isolated from the sample to test for the
presence of DNA viruses; while adenovirus is included in most panels, human bocavirus is
generally not tested for. In rare cases - for instance if a patient has a severe immunodeficiency- it
may also be prudent to test for commonly pathogenic fungi. The overall goal is to be as confident
as possible that the pathogen in a sample is truly unknown or divergent, and not one that is
already established and simply tested for less frequently.

Conclusion
This study advances the development of a method for efficient screening of respiratory viruses
with negative clinical tests for the presence of a possible unknown virus. In one proposed method
clinical nasopharyngeal samples that test negative for all viruses included in a standard
respiratory virus panel can be reflexed to an ELISA to detect the presence of CXCL10, which
indicates an active viral infection. CXCL10-positive samples may then be further evaluated
using NGS and other methods. It is currently not feasible nor would it be necessary to perform
NGS on all respiratory samples; the CXCL10 assay could serve to screen for only samples most
likely to contain truly unknown viruses that would benefit from sequencing or other further
workup. Currently virus discovery/identification is carried out in research studies or based on a
case study of one or two particular patients. A method to screen all clinical samples for the
presence of an unknown virus may be the first step in making sequencing more feasible for
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clinical settings. Additionally, this method could be used to streamline the virus discovery
process or detection of emerging infections.
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Supplemental Tables 1 & 2: Breakdown of symptoms/comorbidities included in each category
from Table 2 and Table 3. Symptoms and comorbidities extracted from patient chart notes.
Symptoms
Cardiac

Altered Mental
State

Respiratory

Fatigue
Fever
Other

Fibrillation
Cardiac arrest
Tachycardia
Chest pain/pressure
Agitation
Paranoia
Altered mental state
Psychosis
Confusion
Delirium
Low O2/desaturation
Pleural effusion
Respiratory failure/hypoxia
Asthma
Chronic Obstructive Pulmonary
Disease (COPD)
Respiratory Distress Syndrome
(RDS)
Pneumonia
Nasopharyngitis
Bronchiolitis
Sore throat
Sinusitis
Shortness of breath/dyspnea
Cough
Fatigue/lethargy
Fever
Chills
Hypo/hypertension
Anemia
Hypo/hyperglycemia
Sickle Cell
Rigors
Hematuria
Seizures
Edema
Acidosis
Dehydration
Abscess/ulcer
Acute Kidney Injury (AKI)
Rash
Planned procedure
Sepsis
Lymphocytosis
Fall
Gastrointestinal symptoms
Headache
Body pain
Malaise
Weakness
Dizziness/syncope

Comorbidities
Liver/Kidney

Cardiovascular

Respiratory

Other

Acute/Chronic Renal Failure
(A/CRF)
CKD
End Stage Renal Disease
(ESRD)
Hepatitis
Kidney failure
Cirrhosis
Aortic aneurysm
Coronary Artery Disease
(CAD)
Cardiac arrest
Cardiomyopathy
Chronic Heart Failure (CHF)
Cystic fibrosis
Emphysema
Interstitial Lung Disease
(ILD)
Pulmonary fibrosis
Chronic respiratory failure
Small airways disease
Pleural effusion
Pulmonary embolism
Tuberculosis
Asthma
Chronic Obstructive
Pulmonary Disease (COPD_
Von Willebrand’s Disease
Grave’s disease
Guillain-Barre syndrome
Graft vs Host Disease
(GVHD)
Kawasaki’s Disease
Lupus
Polycystic Ovarian Syndrome
(PCOS)
Sarcoidosis
Myelodysplastic Syndrome
(MDS)
Sickle cell
Traumatic Brain Injury (TBI)
Recent transplant
Prematurity
Cerebral palsy
Parkinson’s
Schizophrenia
Seizures
CMV
Smoker
Drug/alcohol abuse
Obesity

Diabetes
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